Key facts
- This page summarizes David-Alexandre C. Gros's Form 4 filing for Eledon Pharmaceuticals, Inc. (ELDN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Jan 2025, 17:30.
David-Alexandre C. Gros - 10 Jan 2025 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ELDN
- Reported as of
- 10 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jan 2025, 17:30:09 UTC
- Prior SEC filing
- 22 Nov 2024
- Next SEC filing
- 04 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Little, as attorney-in-fact for David Alexandre C. Gros, M.D.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David-Alexandre C. Gros filed Form 4 for Eledon Pharmaceuticals, Inc. (ELDN) on 13 Jan 2025.
Change
- Previous filing in this sequence was filed on 22 Nov 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELDN
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +600,000
- Change %
- Price
- $0.000000
- Shares after
- 600,000
- Date
- 10 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 600,000
- Exercise price
- $4.04
- Footnotes
- F1
ELDN
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +66,500
- Change %
- Price
- $0.000000
- Shares after
- 66,500
- Date
- 10 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 66,500
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option represents a right to purchase up to 600,000 shares of common stock, which option vests with respect to 150,000 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
Footnote F2
Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.
Footnote F3
Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.